BRPI0820793A2 - Seprase como marcador de câncer - Google Patents

Seprase como marcador de câncer

Info

Publication number
BRPI0820793A2
BRPI0820793A2 BRPI0820793-3A BRPI0820793A BRPI0820793A2 BR PI0820793 A2 BRPI0820793 A2 BR PI0820793A2 BR PI0820793 A BRPI0820793 A BR PI0820793A BR PI0820793 A2 BRPI0820793 A2 BR PI0820793A2
Authority
BR
Brazil
Prior art keywords
cancer
seprase
types
assessment
specific
Prior art date
Application number
BRPI0820793-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Wolfgang Rollinger
Johann Karl
Jarema Peter Kochan
Markus Roessler
Michael Tacke
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP07023897A external-priority patent/EP2071337A1/en
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0820793A2 publication Critical patent/BRPI0820793A2/pt

Links

Classifications

    • G01N33/5752—
    • G01N33/57535—
    • G01N33/57557—
    • G01N33/57565—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96402—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals
    • G01N2333/96405—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals in general
    • G01N2333/96408—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals in general with EC number
    • G01N2333/96411—Serine endopeptidases (3.4.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BRPI0820793-3A 2007-12-10 2008-12-08 Seprase como marcador de câncer BRPI0820793A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07023897A EP2071337A1 (en) 2007-12-10 2007-12-10 Seprase as a marker for cancer
EP08015310 2008-08-29
PCT/EP2008/010385 WO2009074275A1 (en) 2007-12-10 2008-12-08 Seprase as a marker for cancer

Publications (1)

Publication Number Publication Date
BRPI0820793A2 true BRPI0820793A2 (pt) 2015-06-16

Family

ID=40373548

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0820793-3A BRPI0820793A2 (pt) 2007-12-10 2008-12-08 Seprase como marcador de câncer

Country Status (14)

Country Link
US (1) US8980573B2 (enExample)
EP (1) EP2223115B1 (enExample)
JP (1) JP5563988B2 (enExample)
KR (1) KR101202220B1 (enExample)
CN (1) CN101896818B (enExample)
AT (1) ATE524740T1 (enExample)
AU (1) AU2008335855B2 (enExample)
BR (1) BRPI0820793A2 (enExample)
CA (1) CA2706115A1 (enExample)
DK (1) DK2223115T3 (enExample)
ES (1) ES2372442T3 (enExample)
MX (1) MX2010004671A (enExample)
PL (1) PL2223115T3 (enExample)
WO (1) WO2009074275A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8213005B2 (en) 2003-07-22 2012-07-03 King Saud University Method for discriminating between benign and malignant prostate tumors
CA2728153C (en) * 2008-07-03 2015-01-27 F. Hoffmann-La Roche Ag Asc as a marker for lung cancer
NZ600828A (en) 2009-12-20 2014-09-26 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
SI2666872T1 (sl) * 2010-02-05 2016-08-31 Astute Medical, Inc. Postopki in sestavki za diagnozo in prognozo ledvične poškodbe in odpovedi ledvic
WO2012054732A2 (en) * 2010-10-20 2012-04-26 Rush University Medical Center Lung cancer tests
CA2826838A1 (en) * 2011-03-11 2012-09-20 F.Hoffmann-La Roche Ag Seprase as marker for chronic obstructive pulmonary disease (copd)
ES2578477T3 (es) * 2011-03-11 2016-07-27 Roche Diagniostics Gmbh ASC como marcador de la enfermedad pulmonar obstructiva crónica (EPOC)
CN102435748B (zh) * 2011-11-25 2014-07-16 广东药学院 一种双抗夹心酶联免疫检测试剂盒及其制备方法
EP3540440B1 (en) 2011-12-08 2022-09-28 Astute Medical, Inc. Methods and uses for evaluating renal injury and renal status
CA2877721A1 (en) 2012-06-27 2014-01-03 Berg Llc Use of markers in the diagnosis and treatment of prostate cancer
ES2660438T3 (es) 2012-11-09 2018-03-22 F. Hoffmann-La Roche Ag Captura in vitro y análisis de células tumorales circulantes
CA2893158A1 (en) * 2012-11-30 2014-06-05 Applied Proteomics, Inc. Method for evaluation of presence of or risk of colon tumors
EP4105657B1 (en) 2013-01-17 2024-09-25 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US9753037B2 (en) 2013-03-15 2017-09-05 Rush University Medical Center Biomarker panel for detecting lung cancer
CN103267852B (zh) * 2013-05-15 2015-03-25 中国医学科学院北京协和医院 成纤维激活蛋白α在制备胰腺癌预后试剂盒中的用途
KR101619122B1 (ko) 2013-08-14 2016-05-10 연세대학교 산학협력단 탈메틸화 의존적 ａｓｃ 발현을 촉진시켜서 대장암 종양세포의 사멸감수성을 증진시키는 항암제 병용 투여용 후보물질의 스크리닝 방법
WO2015088947A1 (en) 2013-12-09 2015-06-18 Rush University Medical Center Biomarkers of rapid progression in advanced non-small cell lung cancer
PL230661B1 (pl) * 2014-01-29 2018-11-30 Centrum Onkologii Inst Im Marii Sklodowskiej Curie Oddzial W Gliwicach Metoda predykcyjna in vitro do przewidywania i/lub wykluczenia obecnosci raka pluc, zastosowanie in vitro metody predykcyjnej oraz zestaw testowy do wykrywania in vitro raka pluc
EP2916134B1 (en) * 2014-03-05 2017-08-16 Roche Diagnostics GmbH Use of Seprase for differential diagnosis of acute dyspnea
KR102657306B1 (ko) 2014-12-08 2024-04-12 버그 엘엘씨 전립선암의 진단 및 치료에서 필라민을 포함하는 마커의 용도
WO2016146174A1 (en) * 2015-03-17 2016-09-22 Biontech Ag Compositions and methods for diagnosis and treatment of cancer
CA2982169A1 (en) 2015-04-10 2016-10-13 Applied Proteomics, Inc. Protein biomarker panels for detecting colorectal cancer and advanced adenoma
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
CA3029926C (en) * 2016-07-25 2023-01-03 Shizuoka Prefecture Diagnostic biomarker for extrahepatic bile duct cancer, intrahepatic bile duct cancer or gallbladder cancer
US20200237936A1 (en) 2016-12-14 2020-07-30 Purdue Research Foundation Fibroblast activation protein (fap)-targeted imaging and therapy
DE102017010455A1 (de) * 2017-06-13 2018-12-13 Forschungszentrum Jülich GmbH Verfahren zum Nachweis von Aggregaten biotherapeutischer Substanzen in einer Probe
AU2018329359B2 (en) * 2017-09-05 2022-07-14 Oncotag Diagnostics Co., Ltd. Method for diagnosing pancreatic cancer using methionyl-tRNA synthetase, and pancreatic cancer diagnostic kit using same
CN112540176B (zh) * 2020-07-08 2021-09-28 深圳霁因生物医药转化研究院 用于诊断fap表达异常相关疾病的试剂盒、方法及计算机可读存储介质

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0953639A1 (en) * 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
CA2544373A1 (en) * 2003-10-31 2005-05-12 Vitatex, Inc. Blood test prototypes and methods for the detection of circulating tumor and endothelial cells
WO2007001420A2 (en) * 2004-10-22 2007-01-04 Genencor International, Inc. Isolating human antibodies
EP1760076A1 (en) * 2005-09-02 2007-03-07 Ferring B.V. FAP Inhibitors
EP1973548A4 (en) * 2005-12-19 2010-02-24 Tufts College SOFT PROTEASE INHIBITORS AND PRO-SOFT FORMS THEREOF

Also Published As

Publication number Publication date
ATE524740T1 (de) 2011-09-15
KR101202220B1 (ko) 2012-11-16
AU2008335855A1 (en) 2009-06-18
HK1150884A1 (zh) 2012-01-13
AU2008335855B2 (en) 2012-08-30
WO2009074275A1 (en) 2009-06-18
JP2011506941A (ja) 2011-03-03
EP2223115B1 (en) 2011-09-14
JP5563988B2 (ja) 2014-07-30
KR20100091212A (ko) 2010-08-18
US20100240081A1 (en) 2010-09-23
CA2706115A1 (en) 2009-06-18
MX2010004671A (es) 2010-05-27
EP2223115A1 (en) 2010-09-01
CN101896818A (zh) 2010-11-24
PL2223115T3 (pl) 2012-02-29
US8980573B2 (en) 2015-03-17
ES2372442T3 (es) 2012-01-19
DK2223115T3 (da) 2011-12-12
CN101896818B (zh) 2016-01-20

Similar Documents

Publication Publication Date Title
BRPI0820793A2 (pt) Seprase como marcador de câncer
WO2010072383A8 (en) Armet as a marker for cancer
ES2505466T3 (es) Procedimientos para predecir la respuesta al tratamiento del cáncer de mama triple negativo
ES2683362T3 (es) Microvesículas obtenidas a partir de células tumorales
DE602006018578D1 (de) Diagnose- und prognoseverfahren von blasenkrebs.
WO2009074276A3 (en) Marker panel for colorectal cancer
DK2138848T3 (da) Fremgangsmåde til diagnose og/eller prognose af blærecancer
ATE450547T1 (de) Eml4-alk-fusionsgen
WO2010118166A3 (en) Methods of predicting cancer risk using gene expression in premalignant tissue
WO2014140933A3 (en) Method for the prognosis and treatment of cancer metastasis
JP2011521618A5 (enExample)
NZ601022A (en) Diagnosis and treatment of cancer using anti-ereg antibody
ATE551073T1 (de) Markierte hgf-bindende peptide für bildgebung
CY1114111T1 (el) Μεθοδοι χρησης του mirna για την ανιχνευση του in vivo θανατου των κυτταρων
EA201490946A1 (ru) Способ количественной оценки лечения рака
FI2398902T3 (fi) Menetelmiä ja koostumuksia syövän diagnoosia ja hoitoa varten
EA200801046A1 (ru) Неинвазивный способ выявления переходно-клеточной карциномы мочевого пузыря in vitro
EP2021794B8 (en) Use of protein s100a 12 as a marker for colorectal cancer
JP2015007118A5 (enExample)
WO2009015294A8 (en) Biomarkers for human papillomavirus-associated cancers
ATE430936T1 (de) Verwendung von cyfra 21-1 und osteopontin als marker für kolorektalkarzinome
DE602007006671D1 (de) Verwendung von nnmt als marker für lungenkrebs
JP2006311860A5 (enExample)
ATE545867T1 (de) I-plastin-testverfahren zur in-vitro-diagnose von kolorektalkarzinom
DE602005019694D1 (de) Neue proliferationsmarker in der klinischen praxis und deren verwendung zur krebsprognose oder -diagnose

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]